• Search History (Register)
  • MeSH Browser
    • Afrikaans
      Albanian
      Arabic
      Armenian
      Basque
      Bengali
      Bulgarian
      Catalan
      Cambodian
      Chinese (Mandarin)
      Chinese (Cantonese)
      Croatian
      Czech
      Danish
      Dutch
      English
      Estonian
      Fiji
      Finnish
      French
      Georgian
      German
      Greek
      Gujarati
      Hebrew
      Hindi
      Hungarian
      Icelandic
      Indonesian
      Irish
      Italian
      Japanese
      Javanese
      Korean
      Latin
      Latvian
      Lithuanian
      Macedonian
      Malay
      Malayalam
      Maltese
      Maori
      Marathi
      Mongolian
      Nepali
      Norwegian
      Persian
      Polish
      Portuguese
      Punjabi
      Quechua
      Romanian
      Russian
      Samoan
      Serbian
      Slovak
      Slovenian
      Spanish
      Swahili
      Swedish
      Tamil
      Tatar
      Telugu
      Thai
      Tibetan
      Tonga
      Turkish
      Ukrainian
      Urdu
      Uzbek
      Vietnamese
      Welsh
      Xhosa
      Apply
    • Adelaide Health Technology Assessment
      Agence d'évaluation des technologies et des modes d'intervention en santé
      Agencia de Evaluacion de Tecnologias Sanitarias
      Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS)
      Agencia de Qualitat i Avaluacio Sanitries de Catalunya
      Agency for Care Effectiveness (ACE)
      Agency for Health Technology Assessment and Tariff System
      Agency for Healthcare Research and Quality
      Agenzia Sanitaria e Sociale Regionale (Regional Agency for Health and Social Care)
      All Wales Medicines Strategy Group
      Andalusian Health Technology Assessment Area
      Australian Health Technology Advisory Committee
      Australian Safety and Efficacy Register of New Interventional Procedures-Surgical
      Austrian Institute for Health Technology Assessment
      Basque Office for Health Technology Assessment
      Belgian Health Care Knowledge Centre
      BlueCross BlueShield Association
      British Columbia Office of Health Technology Assessment
      Canadian Agency for Drugs and Technologies in Health
      Canadian Coordinating Office for Health Technology Assessment
      Canadian Task Force on Preventive Health Care
      Canary Health Service
      Cellule Innovation of the AP-HP
      Center for Drug Evaluation
      Center for Medical Technology Assessment
      Center for Outcomes Research and Economic Evaluation for Health
      Centre for Clinical Effectiveness
      Centre for Reviews and Dissemination
      Centre for Technology Assessment at the Swiss Science and Technology Council
      Centre Hospitalier de l'Universite de Montreal
      Centre intégré universitaire de santé et de services sociaux de la Capitale-Nationale
      Committee for New Health Technology Assessment
      Conseil d'Evaluation des Technologies de la Santé du Québec
      Coordenação-Geral de Fomento à Pesquisa e Avaliação de Tecnologias em Saúde, Departamento de Ciência e Tecnologia
      Danish Centre for Evaluation and Health Technology Assessment
      Danish Institute for Health Services Research
      ECRI Institute
      European Network for Health Technology Assessment
      Finnish Coordinating Center for Health Technology Assessment
      Finnish Coordinating Center for Health Technology Assessment
      Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Università Cattolica del Sacro Cuore
      German Agency for HTA at the German Institute for Medical Documentation and Information
      Gesundheit Osterreich GmbH
      Hannover Medical School, Medizinische Hochschule Hannover
      Haute Autorité de Santé
      HAYES, Inc.
      Health Council of the Netherlands Gezondheidsraad
      Health Information and Quality Authority (HIQA)
      Health Intervention and Technology Assessment Program
      Health Quality Ontario
      Health Sciences Institute in Aragon (IACS)
      Health Services Assessment Collaboration
      Health Services Utilization and Research Commission
      Health Technology Advisory Committee
      Health Technology and Policy Unit
      Health Technology Assessment Section, Ministry of Health Malaysia
      Health Technology Board for Scotland
      Health Technology Reference Group
      Health Technology Wales
      HTA Region Stockholm
      HTA South
      HTA Unit, University of Calgary
      Institut national d'excellence en sante et en services sociaux
      Institut universitaire de cardiologie et de pneumologie de Québec – Université Laval (IUCPQ-ULaval)
      Institute for Clinical and Economic Review
      Institute for Clinical Effectiveness and Health Policy
      Institute for Clinical Evaluative Sciences
      Institute for Clinical Systems Improvement
      Institute for Quality and Efficiency in Health Care (IQWiG)
      Institute of Applied Health Sciences
      Institute of Health Economics
      Institute of Health Economics
      Institute of Health Technology Assessment and Research (IETSI)
      Institute of Technology Assessment
      Israel Center for Technology Assessment in Health Care
      L'Agence Nationale d'Accreditation d'Evaluation en Santé
      Ludwig Boltzmann Institute for Health Technology Assessment
      Malaysian Health Technology Assessment
      Malaysian Health Technology Assessment Unit
      Medical Advisory Secretariat
      Medical Services Advisory Committee
      Monash Business School, Monash University (MBS)
      National Authority for Assessment and Accreditation in Healthcare (INEAS)
      National Committee for Technology Incorporation (CONITEC)
      National Evidence-based healthcare Collaborating Agency
      National Institute for Clinical Excellence
      National Institute for Health and Care Excellence
      New Zealand Health Technology Assessment
      New Zealand National Health Committee
      NIHR Health and Social Care Delivery Program
      NIHR Health Services and Delivery Research programme
      NIHR Health Technology Assessment programme
      NIHR Horizon Scanning Centre
      NIHR Public Health Research programme
      Norwegian Institute of Public Health
      Norwegian Institute of Public Health
      Norwegian Medical Products Agency
      Ontario Health
      Penn Medicine Center for Evidence-based Practice
      Quality Improvement Scotland
      Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS)
      Scottish Health Purchasing Information Centre
      Scottish Health Technologies Group
      Scottish Medicines Consortium (SMC)
      State Health Care Accreditation Agency under the Ministry of Health of the Republic of Lithuania
      Swedish Agency for Health Technology Assessment and Assessment of Social Services
      Swedish Agency for Health Technology Assessment and Assessment of Social Services
      Swiss Federal Office of Public Health (FOPH)
      Technology Assessment at SickKids
      Technology Assessment Unit of the McGill University Health Centre (MUHC)
      The Danish Health Technology Council
      The Federal Joint Committee
      The HTA Center of the Stockholm County Council/Gotland
      The Italian National Agency for Regional Health Services (Agenas)
      The National Health Care Institute (ZIN, Zorginstituut Nederland)
      The National Health Care Institute (Zorginstituut Nederland)
      The Netherlands Organisation for Health Research and Development
      The Regional Health Technology Assessment Centre
      TNO
      U. S. Congress. Office of Technology Assessment
      Unidad de Evaluacion de Tecnologias Sanitarias
      Unidad de Tecnologias de Salud
      Unit of Health Economics and Technology Assessment in Health Care
      University HealthSystem Consortium
      University of York
      VA Technology Assessment Program
      Washington Singer Press
      Washington State Department of Labor and Industries (WSDLI)
      Wessex Institute for Health Research and Development
      West Midlands Health Technology Assessment Collaboration
      WorkSafeBC
      Apply
    • Afghanistan
      Albania
      Algeria
      Andorra
      Antigua and Barbuda
      Argentina
      Armenia
      Australia
      Austria
      Azerbaijan
      Bahamas
      Bahrain
      Bangladesh
      Barbados
      Belarus
      Belgium
      Belize
      Benin
      Bhutan
      Bolivia
      Bosnia and Herzegovina
      Botswana
      Brazil
      Brunei
      Bulgaria
      Burkina Faso
      Burundi
      Cambodia
      Cameroon
      Canada
      Cape Verde
      Central African Republic
      Chad
      Chile
      China
      Colombia
      Comoros
      Congo
      Costa Rica
      Cote dIvoire
      Croatia
      Cuba
      Cyprus
      Czech Republic
      Denmark
      Djibouti
      Dominica
      Dominican Republic
      East Timor
      Ecuador
      Egypt
      El Salvador
      Equatorial Guinea
      Eritrea
      Estonia
      Ethiopia
      Fiji
      Finland
      France
      Gabon
      Gambia
      Georgia
      Germany
      Ghana
      Greece
      Grenada
      Guatemala
      Guinea
      Guinea-Bissau
      Guyana
      Haiti
      Honduras
      Hong Kong
      Hungary
      Iceland
      India
      Indonesia
      Iran
      Iraq
      Ireland
      Israel
      Italy
      Jamaica
      Japan
      Jordan
      Kazakhstan
      Kenya
      Kiribati
      North Korea
      South Korea
      Kuwait
      Kyrgyzstan
      Laos
      Latvia
      Lebanon
      Lesotho
      Liberia
      Libya
      Liechtenstein
      Lithuania
      Luxembourg
      Macedonia
      Madagascar
      Malawi
      Malaysia
      Maldives
      Mali
      Malta
      Marshall Islands
      Mauritania
      Mauritius
      Mexico
      Micronesia
      Moldova
      Monaco
      Mongolia
      Montenegro
      Morocco
      Mozambique
      Myanmar
      Namibia
      Nauru
      Nepal
      Netherlands
      New Zealand
      Nicaragua
      Niger
      Nigeria
      Norway
      Oman
      Pakistan
      Palau
      Panama
      Papua New Guinea
      Paraguay
      Peru
      Philippines
      Poland
      Portugal
      Puerto Rico
      Qatar
      Romania
      Russia
      Rwanda
      Saint Kitts and Nevis
      Saint Lucia
      Saint Vincent and the Grenadines
      Samoa
      San Marino
      Sao Tome and Principe
      Saudi Arabia
      Senegal
      Serbia and Montenegro
      Seychelles
      Sierra Leone
      Singapore
      Slovakia
      Slovenia
      Solomon Islands
      Somalia
      South Africa
      Spain
      Sri Lanka
      Sudan
      Suriname
      Swaziland
      Sweden
      Switzerland
      Syria
      Taiwan
      Tajikistan
      Tanzania
      Thailand
      Togo
      Tonga
      Trinidad and Tobago
      Tunisia
      Turkey
      Turkmenistan
      Tuvalu
      Uganda
      Ukraine
      United Arab Emirates
      United Kingdom
      United States
      Uruguay
      Uzbekistan
      Vanuatu
      Vatican City
      Venezuela
      Vietnam
      Yemen
      Zambia
      Zimbabwe
      Apply

Welcome to the international HTA database

CSV RIS
Showing [23537 Records] Selected Records [0 Hits] [Clear]
Year Source Title
2021     NIHR Public Health Research (PHR) programme The impact of a family-based physical activity promotion programme on child physical activity: feasibility and pilot of the Families Reporting Every Step to Health (FRESH) intervention.
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Nivolumab (non-small cell lung cancer, combination with ipilimumab) - Benefit assessment according to §35a Social Code Book V]
2021     National Institute for Health and Care Excellence (NICE) Brolucizumab for treating wet age-related macular degeneration. NICE technology appraisal guidance 672
2021     NIHR Health Services and Delivery Research programme Accounting for multimorbidity, competing risk and direct treatment disutility in risk prediction tools and model-based cost-effectiveness analysis for the primary prevention of cardiovascular disease and osteoporotic fracture
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Olaparib (prostate cancer) - Benefit assessment according to §35a Social Code Book V]
2021     National Institute for Health and Care Excellence (NICE) Niraparib for maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy. NICE technology appraisal guidance 673
2021     NIHR Public Health Research (PHR) programme RISKIT-CJS Pragmatic randomized controlled trial to evaluate the effectiveness and cost-effectiveness of a multi-component intervention to reduce substance use and risk-behaviour in adolescents engaged with the criminal justice system
2021     National Authority for Assessment and Accreditation in Healthcare (INEAS) ZELBORAF® (vemurafenib) en monothérapie dans le traitement du mélanome non résécable ou métastatique à mutation BRAF V600
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Acalabrutinib (chronic lymphocytic leukaemia) - Benefit assessment according to §35a Social Code Book V]
2021     National Institute for Health and Care Excellence (NICE) Pembrolizumab for untreated PD-L1-positive, locally advanced or metastatic urothelial cancer when cisplatin is unsuitable (terminated appraisal). NICE technology appraisal guidance 674
2021     NIHR Public Health Research (PHR) programme Evaluating graduated progress towards and impacts of the implementation of indoor smoke free prison facilities in Scotland
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Acalabrutinib (chronic lymphocytic leukaemia; combination with obinutuzumab) - Benefit assessment according to §35a Social Code Book V]
2021     National Institute for Health and Care Excellence (NICE) Vernakalant for the rapid conversion of recent onset atrial fibrillation to sinus rhythm (terminated appraisal). NICE technology appraisal guidance 675
2021     NIHR Health Technology Assessment programme Improving the Wellbeing of people with Opioid Treated CHronic pain; I-WOTCH
2021     The Federal Joint Committee (G-BA) [Pharmaceutical Directive/Annex XII: Luspatercept (β-thalassaemia)]
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Olaparib (adenocarcinoma of the pancreas) - Benefit assessment according to §35a Social Code Book V]
2021     Health Sciences Institute in Aragon (IACS) [Clinical effectiveness of sFlt-1 to PlGF ratio tests for the evaluation of preeclampsia]
2021     National Institute for Health and Care Excellence (NICE) Filgotinib for treating moderate to severe rheumatoid arthritis. NICE technology appraisal guidance 676
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Perampanel (partial-onset seizures) - Benefit assessment according to §35a Social Code Book V]
2021     National Institute for Health and Care Excellence (NICE) Brexucabtagene autoleucel for treating relapsed or refractory mantle cell lymphoma. NICE technology appraisal guidance 677
2021     Austrian Institute for Health Technology Assessment (AIHTA) [Sponsoring of patient initiatives in Austria. Update of the systematic analyses 2014 to 2018]
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Perampanel (generalized epilepsy) - Benefit assessment according to §35a Social Code Book V]
2021     Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S) Effectiveness and safety of vitamin B12 tests
2021     National Institute for Health and Care Excellence (NICE) Omalizumab for treating chronic rhinosinusitis with nasal polyps (terminated appraisal). NICE technology appraisal guidance 678
2021     The Federal Joint Committee (G-BA) [Pharmaceutical Directive/Annex XII: Osilodrostat (Endogenous Cushing’s Syndrome)]
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Durvalumab (small cell lung cancer) - Addendum to Commission A20-87]
2021     Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S) Long-term physiotherapy in patients after stroke, with multiple sclerosis, or with Parkinson's disease
2021     National Institute for Health and Care Excellence (NICE) Dapagliflozin for treating chronic heart failure with reduced ejection fraction. NICE technology appraisal guidance 679
2021     NIHR Health Technology Assessment programme A Phase II randomised clinical trial of conditioning cyclophosphamide and chemoembolisation with or without vaccination with dendritic cells pulsed with HepG2 lysate ex vivo in patients with Hepatocellular Carcinoma: IMMUNOTACE
2021     NIHR Health Technology Assessment programme The cystic fibrosis (CF) anti-staphylococcal antibiotic prophylaxis trial (CF START); a randomised registry trial to assess the safety and efficacy of flucloxacillin as a longterm prophylaxis agent for infants with CF
2021     Austrian Institute for Health Technology Assessment (AIHTA) [Epidemiology of long COVID: a preliminary report. German short version of the original KCE report]
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Durvalumab (small cell lung cancer) - Addendum to Commission A20-87]
2021     National Institute for Health and Care Excellence (NICE) Lenalidomide maintenance treatment after an autologous stem cell transplant for newly diagnosed multiple myeloma. NICE technology appraisal guidance 680
2021     Austrian Institute for Health Technology Assessment (AIHTA) Implantation of bulking agents for faecal incontinence. Update 2021: systematic review
2021     The Federal Joint Committee (G-BA) [Pharmaceutical Directive/Annex XII: Pemigatinib (cholangiocarcinoma with FGFR2 fusion or FGFR2 rearrangement, after at least one prior therapy)]
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Evidence report for the S3 guideline on dementia: Cognitive training / cognitive stimulation]
2021     Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S) Ezetimibe-containing medicines for the treatment of hypercholesterolaemia and mixed/combined hyperlipidaemia
2021     National Institute for Health and Care Excellence (NICE) Baricitinib for treating moderate to severe atopic dermatitis. NICE technology appraisal guidance 681
2021     Austrian Institute for Health Technology Assessment (AIHTA) Percutaneous left ventricular assist devices: micro-axial flow pumps: systematic review
2021     Canary Health Service [Framework for relations between the Spanish Network of HTA agencies of the NHS with industry]
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Afamelanotide (erythropoietic protoporphyria) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V (expiry of the decision)]
2021     Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S) Denosumab (Prolia) for the treatment of osteoporosis
2021     National Institute for Health and Care Excellence (NICE) Erenumab for preventing migraine. NICE technology appraisal guidance 682
2021     Austrian Institute for Health Technology Assessment (AIHTA) Liposuction for surgical therapy of lipoedema: systematic review
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Lumasiran (hyperoxaluria) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V]
2021     Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S) Subacromial decompression as a primary/isolated intervention to treat subacromial pain
2021     National Institute for Health and Care Excellence (NICE) Pembrolizumab with pemetrexed and platinum chemotherapy for untreated, metastatic, non-squamous non-small-cell lung cancer. NICE technology appraisal guidance 683
2021     Institut national d'excellence en sante et en services sociaux (INESSS) [Guidelines and standards: assessment and risk management of severe neurological complications following mild traumatic brain injury]
2021     Austrian Institute for Health Technology Assessment (AIHTA) Triphasic biomaterial for augmentation of the osteoporotic femoral neck: systematic review
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Semaglutide (type 2 diabetes mellitus) - Addendum to Commission A20-93]
2021     Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S) Corneal collagen crosslinking for the treatment of progressive keratoconus
2021     National Institute for Health and Care Excellence (NICE) Nivolumab for adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease. NICE technology appraisal guidance 684
2021     NIHR Health Technology Assessment programme Adrenaline to improve survival in out-of-hospital cardiac arrest: the PARAMEDIC2 RCT
2021     Austrian Institute for Health Technology Assessment (AIHTA) Endoscopic plication therapy in patients with gastroesophageal reflux disease (GERD): systematic review
2021     The Federal Joint Committee (G-BA) [Pharmaceutical Directive/Annex XII: Sebelipase alfa (reassessment after expiry of the deadline (lysosomal acid lipase deficiency))]
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Nivolumab (oesophageal cancer) - Benefit assessment according to §35a Social Code Book V]
2021     National Institute for Health and Care Excellence (NICE) Anakinra for treating Still's disease. NICE technology appraisal guidance 685
2021     Austrian Institute for Health Technology Assessment (AIHTA) Allogenic bone screw Shark Screw® in patients with hallux valgus or scaphoid fractures/pseudarthroses: systematic review
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Dupilumab (atopic dermatitis in children) - Benefit assessment according to §35a Social Code Book V]
2021     National Institute for Health and Care Excellence (NICE) Blinatumomab for previously treated Philadelphia-chromosome-positive acute lymphoblastic leukaemia (terminated appraisal). NICE technology appraisal guidance 686
2021     National Institute for Health and Care Excellence (NICE) Transanal total mesorectal excision for rectal cancer. NICE interventional procedures guidance 713
2021     Austrian Institute for Health Technology Assessment (AIHTA) (Good) practice organisational models using real-world evidence for public funding of high priced therapies
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Lenvatinib (renal cell carcinoma) - Benefit assessment according to §35a Social Code Book V]
2021     National Institute for Health and Care Excellence (NICE) Ribociclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy. NICE technology appraisal guidance 687
2021     National Institute for Health and Care Excellence (NICE) Endobronchial nerve ablation for chronic obstructive pulmonary disease. NICE interventional procedures guidance 714
2021     Austrian Institute for Health Technology Assessment (AIHTA) [Non-interventional studies (NIS) in Austria, 2nd update of systematic analyses 2016 & 2017]
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Carfilzomib (multiple myeloma) - Benefit assessment according to §35a Social Code Book V]
2021     National Institute for Health and Care Excellence (NICE) Selective internal radiation therapies for treating hepatocellular carcinoma. NICE technology appraisal guidance 688
2021     National Institute for Health and Care Excellence (NICE) Percutaneous implantation of pulmonary artery pressure sensors for monitoring treatment of chronic heart failure. NICE interventional procedures guidance 711
2021     Norwegian Institute of Public Health (NIPH) [Autologous stem cell transplantation for multiple sclerosis : rapid scoping review]
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Blinatumomab (acute lymphoblastic leukaemia) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V]
2021     National Institute for Health and Care Excellence (NICE) Acalabrutinib for treating chronic lymphocytic leukaemia. NICE technology appraisal guidance 689
2021     National Institute for Health and Care Excellence (NICE) Coronary sinus narrowing device implantation for refractory angina. NICE interventional procedures guidance 712
2021     Scottish Health Technologies Group (SHTG) Elective surgery using mesh to repair primary or incisional hernias in adults
2021     The Federal Joint Committee (G-BA) [Pharmaceutical Directive/Annex XII: Tagraxofusp (blastic plasmacytoid dendritic cell neoplasm, first-line)]
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Dolutegravir (HIV infection in children aged >= 4 weeks to < 6 years) - Benefit assessment according to §35a Social Code Book V]
2021     National Institute for Health and Care Excellence (NICE) Avelumab for untreated metastatic Merkel cell carcinoma. NICE technology appraisal guidance 691
2021     National Institute for Health and Care Excellence (NICE) Genicular artery embolisation for pain from knee osteoarthritis. NICE interventional procedures guidance 708
2021     Ontario Health Enhanced Visualization Methods for First Transurethral Resection of Bladder Tumour in Suspected Non-muscle-invasive Bladder Cancer: A Health Technology Assessment
2021     Scottish Health Technologies Group (SHTG) A Unique Device Identifier (UDI) system for recording, identifying and recalling medical devices
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Pertuzumab/trastuzumab (breast cancer, neoadjuvant) - Benefit assessment according to §35a Social Code Book V]
2021     National Institute for Health and Care Excellence (NICE) Pembrolizumab for treating locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy. NICE technology appraisal guidance 692
2021     National Institute for Health and Care Excellence (NICE) Laparoscopic renal denervation for loin pain haematuria syndrome. NICE interventional procedures guidance 709
2021     NIHR Health Technology Assessment programme A prognostic model, including quantitative fetal fibronectin, to predict preterm labour: the QUIDS meta-analysis and prospective cohort study
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Niraparib (ovarian cancer) - Benefit assessment according to §35a Social Code Book V]
2021     Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S) Triphasic biomaterial for augmentation of the osteoporotic femoral neck
2021     National Institute for Health and Care Excellence (NICE) Olaparib plus bevacizumab for maintenance treatment of advanced ovarian, fallopian tube or primary peritoneal cancer. NICE technology appraisal guidance 693
2021     National Institute for Health and Care Excellence (NICE) Percutaneous endovascular forearm arteriovenous fistula creation for haemodialysis access. NICE interventional procedures guidance 710
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Fenfluramine (Dravet syndrome) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V]
2021     National Institute for Health and Care Excellence (NICE) Bempedoic acid with ezetimibe for treating primary hypercholesterolaemia or mixed dyslipidaemia. NICE technology appraisal guidance 694
2021     National Institute for Health and Care Excellence (NICE) Lateral elbow resurfacing for arthritis. NICE interventional procedures guidance 705
2021     Institut national d'excellence en sante et en services sociaux (INESSS) [State of practice: evolving profile of the use and clinical outcomes of transcatheter aortic valve implantation (TAVI) and surgical aortic valve implantation (SAVR) in Québec, a real-world evaluation from 2013 to 2019]
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Pertuzumab/trastuzumab (breast cancer, adjuvant) - Benefit assessment according to §35a Social Code Book V]
2021     National Institute for Health and Care Excellence (NICE) Carfilzomib with dexamethasone and lenalidomide for previously treated multiple myeloma. NICE technology appraisal guidance 695
2021     National Institute for Health and Care Excellence (NICE) Transapical transcatheter mitral valve-in-valve implantation for a failed surgically implanted mitral valve bioprosthesis. NICE interventional procedures guidance 706
2021     Canary Health Service [Molecular markers for the detection of clinically significant prostate cancer]
2021     Health Technology Wales (HTW) Extracorporeal shockwave therapy for the treatment of musculoskeletal conditions
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Pertuzumab/trastuzumab (breast cancer, first line) - Benefit assessment according to §35a Social Code Book V]
2021     National Institute for Health and Care Excellence (NICE) Tafamidis for treating transthyretin amyloidosis with cardiomyopathy. NICE technology appraisal guidance 696
2021     National Institute for Health and Care Excellence (NICE) Transapical transcatheter mitral valve-in-ring implantation after failed annuloplasty for mitral valve repair. NICE interventional procedures guidance 707